Study: Aflibercept superior to laser for ME due to BRVO
West Columbia, SC—Primary outcome data from a phase III clinical trial evaluating aflibercept (Eylea, Regeneron) for macular edema (ME) due to branch retinal vein occlusion (BRVO) show that intravitreal treatment with the anti-VEGF agent was well tolerated and associated with significantly better improvements in visual acuity and central retinal thickness (CRT) than laser photocoagulation.
W. Lloyd Clark, MD— a retinal specialist in private practice, Palmetto Retina Center, West Columbia, SC—reported the data from the 24-week visit in the ongoing VIBRANT study.
The double-masked trial randomly assigned 183 patients 1:1 to monthly injections of aflibercept 2 mg or laser. Eligible patients had center-involved ME diagnosed within 12 months of screening, best-corrected visual acuity between 20/40 and 20/320, sufficient clearing of intraretinal hemorrhage to allow for baseline laser treatment, and were treatment naïve.
The two treatment groups were well balanced in their demographic and baseline disease characteristics, and more than 90% of patients in both treatment arms completed the primary outcome visit at week 24. Patients in the laser group could be re-treated at week 12 if they met protocol-specified re-treatment criteria, and most received a second treatment. Patients in the aflibercept group received a mean of 5.7 injections.
MORE ARTICLES IN THIS ISSUE
BioLight Israeli Life Sciences Investments’ subsidiary, ViSci, has filed an investigational new drug (IND) application with the FDA to conduct a phase I/IIa clinical study with its treatment for glaucoma—a subconjunctival Latanoprost controlled-release insert.
The FDA has granted 510(k) clearance to Escalon Medical Corp.’s tablet-based ultrasound imaging system, the Sonomed Escalon VuPad.
Novaliq GmbH has announced the commencement of a phase I study for its dry eye syndrome treatment, cyclosporine solution (CyclASol), following United States and European patent approval.